Factors associated with depression during the perimenopausal transition.

Background: This paper examines the factors associated with depressive symptoms during the perimenopausal transition, to increase the understanding about the etiology of perimenopausal depression.

Method: Seventy-six peri- and early postmenopausal women with or without current depressive symptoms were recruited (mean, 49.5 years; standard deviation, 4.

What factors determine whether a woman becomes depressed during the perimenopause?

Perimenopause has long been associated with psychological distress, both anecdotally and clinically. Research has identified this time as a period of increased risk for both first-episode depression and for depression reoccurrence. However, we know that the majority of women do not experience these difficulties during perimenopause.

Hormonal therapies for new onset and relapsed depression during perimenopause.

In recent years the perimenopause has become recognised as a 'window of vulnerability' for women's mood. The risk of depression during perimenopause is high and treatment failure is common. Perimenopausal depression encompasses both new onset (first episode) depression occurring during perimenopause as well as a relapse during perimenopause in women with a history of depression.

Strength and functional characteristics of men and women 65 years and older.

Background: Resistance training programs for older adults (>65 years) are an effective method to counteract the loss of muscle mass, strength, and function associated with aging. Nevertheless, limited normative strength and functional data exist for the comparison and stratification of older adults. Therefore, the purpose of this study was to establish normative strength and functional data for males and females 64-69 years, 70-74 years, and 75+ years old, using commonly available equipment and procedures.

Rescue of Abeta(1-42)-induced memory impairment in day-old chick by facilitation of astrocytic oxidative metabolism: implications for Alzheimer's disease.

Administration of small oligomeric beta-amyloid (Abeta)(1-42) 45 min before one-trial bead discrimination learning in day-old chicks abolishes consolidation of learning 30 min post-training (Gibbs et al. Neurobiol. Aging, in press).

Memory loss caused by beta-amyloid protein is rescued by a beta(3)-adrenoceptor agonist.

Accumulation of the neurotoxic beta-amyloid protein (Abeta) in the brain is a key step in the pathogenesis of Alzheimer's disease (AD). Although transgenic mouse models of AD have been developed, there is a clear need for a validated animal model of Abeta-induced amnesia which can be used for toxicity testing and drug development. Intracranial injections of Abeta(1-42) impaired memory in a single trial discriminative avoidance learning task in chicks.